Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

3SBio is a leading biotech drugmaker in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005, which are market-leading innovative drugs.

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

About 3SBio Inc. 3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.

3SBio has good financial health. As of 2020, total debt was CNY 3 billion, net debt was minus CNY 218 million, and net debt to equity was negative 2%. The company generates approximately CNY 1 ...

Pharmaceutical giant Pfizer Inc.PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 ...

Research outputs, collaborations and relationships for 3SBio Nature Index 2025 Cancer From personalized vaccines to next-generation screening technologies, the ways the world treats and detects ...

3SBio, Inc. operates as an investment holding company, which engages in the development, production, marketing, and sale of biopharmaceutical products. Its products are used in the field of ...